R-ketorolac as a GTPase inhibitor: phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients

Muller, Carolyn

135 - Focused Plenary
R-ketorolac as a GTPase inhibitor: phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients

Monday, March 24, 2014: 4:23 PM

Ballroom B/C (Tampa Convention Center)

C. Muller¹, L. G. Hudson¹, S. R. Kenney¹, Y. Guo¹, M. Gaede¹, S. F. Adams², T. Rutledge¹ and A. Wandinger-Ness¹
¹University of New Mexico, Albuquerque, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

135 - Focused Plenary
R-ketorolac as a GTPase inhibitor: phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients

135 - Focused Plenary R-ketorolac as a GTPase inhibitor: phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients

135 - Focused Plenary
R-ketorolac as a GTPase inhibitor: phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients